Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16777585rdf:typepubmed:Citationlld:pubmed
pubmed-article:16777585lifeskim:mentionsumls-concept:C0038013lld:lifeskim
pubmed-article:16777585lifeskim:mentionsumls-concept:C0596707lld:lifeskim
pubmed-article:16777585lifeskim:mentionsumls-concept:C0205164lld:lifeskim
pubmed-article:16777585pubmed:issue3lld:pubmed
pubmed-article:16777585pubmed:dateCreated2006-6-16lld:pubmed
pubmed-article:16777585pubmed:abstractTextThe association of HLA-B27 with ankylosing spondylitis accounts for nearly 40% of the total disease risk. However, fewer than 5% of B27-positive individuals in the general population become affected. Genomewide scans suggest that other major histocompatibility complex genes further heighten this risk, although linkage disequilibrium with HLA-B27 has confounded their precise identification. Over 31 variants of HLA-B27 have been identified to date, which have evolved from the original B27 allele (B*2705) along three geographic lines. HLA-B*2705 and B*2702 are the primary subtypes in Caucasians with spondylitis, and B*2704 and B*2707 are the primary subtypes in Asians. HLA-B*2706 and B*2709 are not disease associated. There are four theories of how HLA-27 causes spondyloarthritis: (1) HLA-B27 presents a bacterially derived 'arthritogenic peptide' (not yet identified); (2) misfolding or homodimerization of HLA-B27 heavy chains results in a pro-inflammatory response; (3) HLA-B27-positive individuals have deficient intracellular killing of arthritogenic organisms; and (4) HLA-B27 itself, due to sequence homology with bacterial proteins, becomes autoantigenic.lld:pubmed
pubmed-article:16777585pubmed:languageenglld:pubmed
pubmed-article:16777585pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16777585pubmed:citationSubsetIMlld:pubmed
pubmed-article:16777585pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16777585pubmed:statusMEDLINElld:pubmed
pubmed-article:16777585pubmed:monthJunlld:pubmed
pubmed-article:16777585pubmed:issn1521-6942lld:pubmed
pubmed-article:16777585pubmed:authorpubmed-author:ReveilleJohn...lld:pubmed
pubmed-article:16777585pubmed:issnTypePrintlld:pubmed
pubmed-article:16777585pubmed:volume20lld:pubmed
pubmed-article:16777585pubmed:ownerNLMlld:pubmed
pubmed-article:16777585pubmed:authorsCompleteYlld:pubmed
pubmed-article:16777585pubmed:pagination601-9lld:pubmed
pubmed-article:16777585pubmed:meshHeadingpubmed-meshheading:16777585...lld:pubmed
pubmed-article:16777585pubmed:meshHeadingpubmed-meshheading:16777585...lld:pubmed
pubmed-article:16777585pubmed:meshHeadingpubmed-meshheading:16777585...lld:pubmed
pubmed-article:16777585pubmed:meshHeadingpubmed-meshheading:16777585...lld:pubmed
pubmed-article:16777585pubmed:meshHeadingpubmed-meshheading:16777585...lld:pubmed
pubmed-article:16777585pubmed:meshHeadingpubmed-meshheading:16777585...lld:pubmed
pubmed-article:16777585pubmed:meshHeadingpubmed-meshheading:16777585...lld:pubmed
pubmed-article:16777585pubmed:year2006lld:pubmed
pubmed-article:16777585pubmed:articleTitleMajor histocompatibility genes and ankylosing spondylitis.lld:pubmed
pubmed-article:16777585pubmed:affiliationDivision of Rheumatology, The University of Texas Health Science Center at Houston, 6431, Fannin, TX 77030 , USA. john.d.reveille@uth.tmc.edulld:pubmed
pubmed-article:16777585pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16777585pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16777585lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16777585lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16777585lld:pubmed